ritanserin has been researched along with Atherosclerotic Parkinsonism in 1 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ritanserin is a new compound with a high, selective, and long-lasting binding affinity for 5-HT2 receptors." | 2.67 | 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. ( Bersani, G; Ciani, N; Grispini, A; Marini, S; Pasini, A; Valducci, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bersani, G | 1 |
| Grispini, A | 1 |
| Marini, S | 1 |
| Pasini, A | 1 |
| Valducci, M | 1 |
| Ciani, N | 1 |
1 trial available for ritanserin and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Orphenadrine; Parkinson D | 1990 |